This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Sagami Chemical Research Center. Active years: 1985.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1985
Title: Kumi Kobayashi: Innovator in Pharmaceutical Intermediates
Introduction
Kumi Kobayashi is a notable inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceuticals through her innovative work. Her research focuses on the development of optically active compounds that serve as important intermediates in drug manufacturing.
Latest Patents
Kumi Kobayashi holds a patent for an invention titled "Optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl)." This patent describes a manufacturing method for the preparation of optically active 1-(6-methoxy-2-naphthyl)-2-(alkoxycarbonyl)amino-1-propanone, along with its derivatives and halo analogs. The optically active compounds produced are useful intermediates in the preparation of 2-(6-methoxy-2-naphthyl)propionic acid, which has applications as a pharmaceutical agent, including anti-inflammatory, analgesic, and anti-pyretic properties.
Career Highlights
Kumi Kobayashi is affiliated with the Sagami Chemical Research Center, where she continues to advance her research in the field of chemical synthesis and pharmaceutical development. Her work has garnered attention for its potential impact on drug formulation and therapeutic applications.
Collaborations
Kumi has collaborated with esteemed colleagues such as Genichi Tsuchihashi and Shuichi Mitamura. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the pharmaceutical sector.
Conclusion
Kumi Kobayashi's contributions to the field of pharmaceuticals through her innovative patents and collaborative efforts highlight her role as a key inventor in the industry. Her work continues to pave the way for advancements in drug development and therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile